Informing relatives of their genetic risk: an examination of the Belgian legal context

2022 ◽  
Author(s):  
Amicia Phillips ◽  
Thomas Bronselaer ◽  
Pascal Borry ◽  
Ine Van Hoyweghen ◽  
Danya F. Vears ◽  
...  
Keyword(s):  
Genetic Risk ◽  
Legal Context

Confession Evidence in Canada: Psychological Issues in the Legal Context

2009 ◽  
Author(s):  
Steven M. Smith ◽  
Veronica Stinson ◽  
Marc W. Patry
Keyword(s):  
Psychological Issues ◽  
Legal Context ◽  
Confession Evidence

Heterozygosity for the alpha1-antitrypsin Z allele confers high genetic risk of cholangiocarcinoma

2010 ◽  
Vol 48 (08) ◽  
Author(s):  
V Zimmer ◽  
F Mihalache ◽  
A Höblinger ◽  
F Grünhage ◽  
M Krawczyk ◽  
...  
Keyword(s):  
Genetic Risk ◽  
High Genetic Risk ◽  
Alpha1 Antitrypsin

A Mutation in Plasma Platelet-activating Factor Acetylhydrolase (Val279Phe) Is a Genetic Risk Factor for Cerebral Hemorrhage but not for Hypertension

1998 ◽  
Vol 80 (09) ◽  
pp. 372-375 ◽  
Author(s):  
Hidemi Yoshida ◽  
Tadaatsu Imaizumi ◽  
Koji Fujimoto ◽  
Hiroyuki Itaya ◽  
Makoto Hiramoto ◽  
...  
Keyword(s):  
Risk Factor ◽  
Genetic Risk ◽  
Platelet Activating Factor ◽  
Vascular Diseases ◽  
Genetic Risk Factor ◽  
Brain Hemorrhage ◽  
Platelet Activating Factor Acetylhydrolase ◽  
Paf Acetylhydrolase ◽  
Polymerase Chain ◽  
The Difference

SummaryPlatelet-activating factor (PAF) acetylhydrolase is an enzyme that inactivates PAF. Deficiency of this enzyme is caused by a missense mutation in the gene. We previously found a higher prevalence of this mutation in patients with ischemic stroke. This fact suggests that the mutation might enhance the risk for stroke through its association with hypertension. We have addressed this hypothesis by analyzing the prevalence of the mutation in hypertension. We studied 138 patients with essential hypertension, 99 patients with brain hemorrhage, and 270 healthy controls. Genomic DNA was analyzed for the mutant allele by the polymerase-chain reaction. The prevalence of the mutation was 29.3% (27.4% heterozygotes and 1.9% homozygotes) in controls and 36.2% in hypertensives and the difference was not significant. The prevalence in patients with brain hemorrhage was significantly higher than the control: 32.6% heterozygotes and 6.1% homozygotes (p <0.05). PAF acetylhydrolase deficiency may be a genetic risk factor for vascular diseases.

Sign in / Sign up

Export Citation Format

Share Document